In close collaboration with an external partner, the Maybridge collection includes target-specified libraries of drug-like compounds created by applying different computational methodologies based upon bioinformatics and structure-based drug discovery. These focused screening libraries of compounds are cherry-picked from available fragment collections to facilitate the discovery of novel chemical entities exhibiting specific biological activities or to screen against certain molecular or biological targets.
Our highly targeted screening libraries have been shown to have substantially high hit rates, examples of which include:
- Antiviral library—over 8,000 compounds chosen to facilitate the discovery of novel chemical entities with profound antiviral activity and improved safety profiles
- Antibacterial library—over 8,000 compounds that form a unique compound library for antibacterial research based on the proprietary natural product like scaffolds that provide great skeletal diversity combined with the presence of polar functional groups and multiple stereogenic centers
- Protein-protein Interaction (PPI) library—over 11,000 compounds selected through analysis of the PPI-relevant chemical space and development of several strategies for building PPI-focused chemical libraries
- GPCR library—over 10,000 compounds selected for screening against G-protein-coupled receptors
- Kinase library—over 6,000 compounds chosen to facilitate the discovery of novel kinase inhibitors by providing access to our advanced collection of small molecules, fragments, and macrocycles; the efficacy of our compounds has been validated through in silico modeling and in vitro on-target phenotypic profiling
- Ion channel library—a compound library designed on principles based upon a pharmacophore analysis of known ion channel blockers
Other focused libraries (such as libraries of compounds that screen against histone deacetylase (HDAC) inhibitors) are available upon request.
For Research Use Only. Not for use in diagnostic procedures.